FORT LAUDERDALE, Fla. — Patients with intermediate age-related macular degeneration treated with intravitreal aflibercept injections did not experience improved rates of non-conversion to neovascular age-related macular degeneration after 12 months of treatment, according to a speaker here.
“Interim analysis did not demonstrate a benefit of intravitreal aflibercept injection as a prophylactic treatment against conversion to neovascular AMD in high-risk eyes,” said Sumit P. Shah, MD, FACS, at Retina World Congress.
Shah presented the 12-month interim results of the 24-month
Uncategorized